Korsana Biosciences Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Korsana Biosciences Inc.
- Former names
- Cyclerion Therapeutics, Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Massachusetts
- Headquarters city
- Waltham
- Headquarters state / province
- Massachusetts
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- KRSA
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001755237
- EIN
- 83-1895370
Board of directors
-
Andrew Gottesdiener · DirectorSince 2026
-
Dina Katabi · DirectorSince 2023
-
Errol B. Desouza · DirectorSince 2023
-
Heidi Henson · DirectorSince 2026
-
Jonathan Violin · Director · See RemarksSince 2026
-
Michael J. Higgins · DirectorSince 2023
-
Michelle Patricia Pernice · DirectorSince 2026
-
Nimish P. Shah · DirectorSince 2026
- Since 2026
-
Peter M. Hecht · DirectorSince 2023
-
Regina Margaret Graul · Director · See RemarksSince 2024
-
Steven Hyman · DirectorSince 2023
- Since 2023
- Since 2026
Director election results
Annual meeting of August 26, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
99.7%
-
99.9%
-
99.9%
-
99.9%
-
99.9%
Board connections
8 of this board's directors also sit on 20 other boards.
- via Jonathan Violin, Peter Evan Harwin and Tomas Kiselak
- via Jonathan Violin, Peter Evan Harwin and Tomas Kiselak
- via Jonathan Violin, Peter Evan Harwin and Tomas Kiselak
- via Errol B. Desouza and Terrance Mcguire
- via Peter Evan Harwin and Tomas Kiselak
- via Peter Evan Harwin and Tomas Kiselak
- via Peter Evan Harwin and Tomas Kiselak
- via Michael J. Higgins and Steven Hyman
- via Peter Evan Harwin and Tomas Kiselak
- via Michael J. Higgins
- via Peter Evan Harwin
- via Peter Evan Harwin
- via Terrance Mcguire
- via Heidi Henson
- via Heidi Henson
- via Heidi Henson
- via Michael J. Higgins
- via Errol B. Desouza
- via Terrance Mcguire
- via Terrance Mcguire
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 14, 2026 | CHICKO RHONDA M. Officer (Chief Financial Officer) | Option exercise | +25,000 | $2.36 | $58,875 |
| Aug 14, 2026 | Regina Margaret Graul Director, Officer (See Remarks) | Option exercise | +55,849 | $3.30 | $184,302 |
| Aug 14, 2026 | Regina Margaret Graul Director, Officer (See Remarks) | Shares withheld for tax | −48,629 | $3.79 | $184,304 |
| Jul 16, 2026 | Peter M. Hecht Director, 10% owner | Derivative conversion | +351,037 | — | — |
| Mar 25, 2025 | Peter M. Hecht Director, 10% owner | Grant or award | +181,818 | $2.75 | $500,000 |
| Mar 25, 2025 | Michael J. Higgins Director | Grant or award | +9,090 | $2.75 | $24,998 |
| Nov 21, 2024 | Greenspan David Gerald 10% owner | Open-market sale | −357,880 | $1.55 | $554,714 |
| Jan 1, 2024 | Peter M. Hecht Director, 10% owner | Grant or award | +15,000 | — | — |
| Jan 1, 2024 | Graul Regina Margaret Officer (President) | Grant or award | +50,000 | — | — |
| Dec 1, 2023 | Peter M. Hecht Director, 10% owner | Grant or award | +15,000 | — | — |
| Nov 30, 2023 | Terrance Mcguire Director | Grant or award | +5,000 | — | — |
| Nov 30, 2023 | Peter M. Hecht Director, 10% owner | Grant or award | +20,000 | — | — |
| Nov 30, 2023 | Errol B. Desouza Director | Grant or award | +20,000 | — | — |
| Nov 30, 2023 | Steven Hyman Director | Grant or award | +20,000 | — | — |
| Nov 30, 2023 | Errol B. Desouza Director | Grant or award | +30,000 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.